Showing 2 posts in Laws & Regulations.
Thank you to all who joined us for our Data Privacy Rx Conference on May 26, 2015. Clearly data privacy and cyber security are among the top issues organizations face today. Read More ›
May a court certify a class that includes members who suffered no injury? The First Circuit will hear arguments on this issue at the end of this month. The case, In re Nexium (Esomeprazole) Antitrust Litigation, has the potential to provide another powerful weapon with which defendants can defeat class certification in certain cases. Plaintiffs allege that the defendants, AstraZeneca, the manufacturer of the brand drug Nexium, and three manufacturers of generic versions of Nexium, violated antitrust laws when, to settle claims of infringement on AstraZeneca’s Nexium patent, the generic manufacturers agreed to delay the release of the generic drugs in exchange for payments from AstraZeneca. The named plaintiffs, ten union health and welfare funds, sought to certify a class of all customers and third party payors (“TPPs”) who purchased or paid for Nexium in the states that allow for antitrust actions by indirect purchasers. Read More ›
Ask the Blogger
Do you have a topic that you would like discussed in a future blog article? Please let us know. If you have a confidential question regarding a blog article, please feel free to contact the article's author directly, or let us know if you would like for someone to contact you directly.
Stephen E. Embry is a member of the Firm's class action, privacy and mass tort groups. He frequently defends participants in consumer class actions and mass tort litigation. Stephen is a national litigator and advisor who is experienced in developing solutions to complex litigation and corporate problems.